The authors found that tideglusib (TID) markedly reduced the cell viability of different osteosarcoma cell lines. Cell cycle arrest distributed in G2/M was markedly up-regulated in TID-incubated osteosarcoma cells through enhancing p21 expression levels.
[Biochemical and Biophysical Research Communications]
Wei, D., Zhu, X., Li, S., Liu, G., Wang, Y., Wang, W., Zhang, Q., & Jiang, S. (2021). Tideglusib suppresses stem-cell-like features and progression of osteosarcoma by inhibiting GSK-3β/NOTCH1 signaling. Biochemical and Biophysical Research Communications, 554, 206–213. https://doi.org/10.1016/j.bbrc.2020.12.055 Cite
0